Merck & Co. Stock News

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced new clinical and outcomes research data on pulmonary arterial hypertension (PAH) to be presented at the American Thoracic Society's (ATS) 2025 International Conference in San Francisco from May 16-21. Data from nine presentations demonstrate Merck's commitment to advancing res...

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Announces Positive Topline Results of Phase 3 KEYNOTE-B96 Trial In Patients With Platinum-Resistant Recurrent Ovarian Cancer.

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--WELIREG PPGL FDA Approval News Release.

Merck & Co., Inc. (NYSE:MRK ) BofA Securities 2025 Healthcare Conference May 14, 2025 1:40 PM ET Company Participants Jannie Oosthuizen - President Peter Dannenbaum - Senior Vice President, Investor Relations Marjorie Green - SVP, Head of Oncology Clinical Development Conference Call Participants Tim Anderson - Bank of America Tim Anderson Thanks for joining us for this, meeting. I'm Tim Anders...

The U.S. Food and Drug Administration said on Wednesday it has approved the expanded use of Merck's cancer drug to treat two types adrenal gland tumors.

Buying low and selling high is what investing comes down to. Often, however, investors get spooked when prices are low and avoid struggling stocks, thinking that they are destined to go even lower.

Uncertainty around pharma tariffs on and pricing policies under the Trump has much of the sector guessing what will happen next.

German healthcare and materials group Merck KGaA has dropped a surcharge on life sciences sector orders within China following the U.S.-China agreement to pause sky-high tariffs on each other, the company said Wednesday.